Neogen Provides Update on Genomics Business Sale, Expects Regulatory Review Conclusion Early 2027

Neogen Corporation has provided an update on the pending sale of its global Genomics business to Zoetis Inc., originally announced on March 2, 2026. The transaction is currently under regulatory review in Australia and New Zealand, and a proposed asset divestiture by Zoetis is expected to help secure approval.

Key Details

• Transaction: The definitive agreement to sell Neogen's global Genomics business to Zoetis Inc., announced on March 2, 2026.
• Regulatory Update: The deal is under review by the Australian Competition and Consumer Commission (ACCC) and the New Zealand Commerce Commission (NZCC). To assist the approval process, Zoetis has offered to divest certain assets in Australia.
• Revised Timeline: As a result of the proposed divestiture, Neogen now expects the regulatory review process to conclude in early 2027.